Clinical Trials Register

Summary
EudraCT Number:	2020-004381-19
Sponsor's Protocol Code Number:	NBI-74788-CAH2006
National Competent Authority:	Spain - AEMPS
Clinical Trial Type:	EEA CTA
Trial Status:	Ongoing
Date on which this record was first entered in the EudraCT database:	2021-08-13
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2020-004381-19

A.3

Full title of the trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de crinecerfont (NBI-74788) en sujetos pediátricos con hiperplasia suprarrenal congénita clásica, seguido de un tratamiento abierto

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia

Estudio para Evaluar la Seguridad y la Eficacia de crinecerfont en pacientes pediátricos con hiperplasia suprarrenal congénita clásica.

A.4.1

Sponsor's protocol code number

NBI-74788-CAH2006

A.7

Trial is part of a Paediatric Investigation Plan

Yes

A.8

EMA Decision number of Paediatric Investigation Plan

P/104/2021

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Neurocrine Biosciences, Inc.
B.1.3.4	Country	United States
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Neurocrine Biosciences, Inc.
B.4.2	Country	United States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Accelsiors CRO and Consultancy Services Ltd.
B.5.2	Functional name of contact point	Regulatory Unit
B.5.3	Address:
B.5.3.1	Street Address	103 Haros Str
B.5.3.2	Town/ city	Budapest
B.5.3.3	Post code	1222
B.5.3.4	Country	Hungary
B.5.4	Telephone number	+361299 00 91
B.5.5	Fax number	+361299 00 96
B.5.6	E-mail	regulatory@accelsiors.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	Yes
D.2.5.1	Orphan drug designation number	EU/3/19/2194
D.3 Description of the IMP
D.3.1	Product name	Crinecerfont
D.3.2	Product code	NBI-74788
D.3.4	Pharmaceutical form	Capsule, hard
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Crinecerfont
D.3.9.1	CAS number	752253-39-7
D.3.9.2	Current sponsor code	NBI-74788
D.3.9.4	EV Substance Code	SUB197132
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	50
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	Yes
D.2.5.1	Orphan drug designation number	EU/3/19/2194
D.3 Description of the IMP
D.3.1	Product name	Crinecerfont
D.3.2	Product code	NBI-74788
D.3.4	Pharmaceutical form	Oral solution
D.3.4.1	Specific paediatric formulation	Yes
D.3.7	Routes of administration for this IMP	Other use (Noncurrent) Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Crinecerfont
D.3.9.1	CAS number	752253-39-7
D.3.9.2	Current sponsor code	NBI-74788
D.3.9.4	EV Substance Code	SUB197132
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	50
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Capsule, hard
D.8.4	Route of administration of the placebo	Oral use
D.8 Placebo: 2
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Oral solution
D.8.4	Route of administration of the placebo	Oral use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Classic Congenital Adrenal Hyperplasia (CAH)

Hiperplasia Suprarrenal Congénita Clásica

E.1.1.1

Medical condition in easily understood language

Congenital adrenal hyperplasia (CAH) is a group of rare inherited endocrine disorders characterized by a deficiency of one of the enzymes needed to make specific hormones.

Hiperplasia suprarrenal congénita(CAH) es 1 grupo de trastornos endocrinos hereditarios poco frecuentes caracterizado por la deficiencia de una enzima necesaria para producir hormonas específicas.

E.1.1.2

Therapeutic area

Diseases [C] - Hormonal diseases [C19]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	20.0
E.1.2	Level	LLT
E.1.2	Classification code	10010323
E.1.2	Term	Congenital adrenal hyperplasia
E.1.2	System Organ Class	100000004850

E.1.3

Condition being studied is a rare disease

Yes

E.2 Objective of the trial

E.2.1

Main objective of the trial

• To evaluate the efficacy of crinecerfont, compared with placebo, in reducing adrenal steroid levels during a glucocorticoid-stable period.
• To evaluate the efficacy of crinecerfont, compared with placebo, in reducing daily glucocorticoid dosage while maintaining adrenal androgen control.
• To evaluate the effect of crinecerfont, compared with placebo, on clinical endpoints associated with supraphysiologic glucocorticoid dosing and androgen excess.
• To evaluate plasma concentrations of crinecerfont and metabolites.
• To assess the safety and tolerability of crinecerfont.

• Evaluar la eficacia de crinecerfont, en comparación con placebo, en la reducción de los niveles de esteroides suprarrenales durante un periodo estable con glucocorticoides.
• Evaluar la eficacia de crinecerfont, en comparación con placebo, en la reducción de la dosis diaria de glucocorticoides mientras se mantiene el control androgénico suprarrenal.
• Evaluar el efecto de crinecerfont, en comparación con placebo, en los criterios de valoración clínicos asociados a la administración suprafisiológica de glucocorticoides y el exceso de andrógenos.
• Evaluar las concentraciones plasmáticas de crinecerfont y sus metabolitos.
• Evaluar la seguridad y la tolerabilidad de crinecerfont.

E.2.2

Secondary objectives of the trial

Not Applicable

No Aplica

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

- Be willing and able to adhere to the study procedures, including all requirements at the study center and return for the follow-up visit.
- Be a female or male 2 to 17 years of age with a body weight of at least 10 kg.
- Have a medically confirmed diagnosis of classic CAH due to 21- hydroxylase deficiency.
- Be on a stable regimen of glucocorticoid treatment for CAH.
- Have elevated adrenal androgens.
- If treated with fludrocortisone, be on a stable regimen with plasma renin activity (PRA) indicating adequate replacement.

- Estar dispuesto y ser capaz de cumplir con los procedimientos del estudio, incluidos todos los requisitos en el centro del estudio y relizar la visita de seguimiento.
- Ser mujer o hombre de 2 a 17 años con un peso corporal de al menos 10 kg.
- Tener un diagnóstico médicamente confirmado de CAH clásica por deficiencia de 21-hidroxilasa.
- Estar en un régimen estable de tratamiento con glucocorticoides para la CAH.
- Tener andrógenos suprarrenales elevados.
- Si se trata con fludrocortisona, mantenerse en un régimen estable con actividad de renina plasmática (ARP) que indique un reemplazo adecuado.

E.4

Principal exclusion criteria

- Have a diagnosis of any of the other forms of classic CAH.
- Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic daily therapy with oral glucocorticoids.
- Have a clinically significant unstable medical condition or chronic disease other than CAH
- Have a history of malignancy, unless successfully treated with curative intent and considered to be cured.
- Have a known history of clinically significant arrhythmia or abnormalities on screening ECG.
- Have a known hypersensitivity or allergy to any corticotropin-releasing hormone (CRH) receptor antagonist.
- Females who are pregnant or lactating.

- Tener un diagnóstico de cualquiera de las otras formas de CAH clásica.
- Tener antecedentes de adrenalectomía bilateral, hipopituitarismo u otra afección que requiera tratamiento diario crónico con glucocorticoides orales.
- Tener una condición médica inestable clínicamente significativa o una enfermedad crónica que no sea CAH
- Tener antecedentes de malignidad, a menos que se trate con éxito con intención curativa y se considere curado.
- Tener antecedentes conocidos de arritmias o anomalías clínicamente significativas en el ECG de detección.
- Tener hipersensibilidad conocida o alergia a cualquier antagonista del receptor de la hormona liberadora de corticotropina (CRH).
- Mujeres embarazadas o en período de lactancia.

E.5 End points

E.5.1

Primary end point(s)

Change from baseline in serum androstenedione at Week 4.

Cambio del valor inicial en la androstenediona sérica en la semana 4.

E.5.1.1

Timepoint(s) of evaluation of this end point

Week 4

Semana 4

E.5.2

Secondary end point(s)

- Percent change from baseline in glucocorticoid dose at Week 28
- Change from baseline in serum 17-hydroxyprogesterone at Week 4

- Cambio porcentual desde el valor inicial en la dosis de glucocorticoides en la semana 28
- Cambio con respecto al valor inicial en la 17-hidroxiprogesterona sérica en la semana 4

E.5.2.1

Timepoint(s) of evaluation of this end point

Week 4 and Week 28

Semana 4 y Semana 28

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

Yes

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

Yes

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Canada

United States

Belgium

France

Germany

Italy

Poland

Spain

Sweden

Greece

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

UVUS

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

Yes

F.1.1

Number of subjects for this age range:

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

Yes

F.1.1.5.1

Number of subjects for this age range:

F.1.1.6

Adolescents (12-17 years)

Yes

F.1.1.6.1

Number of subjects for this age range:

F.1.2

Adults (18-64 years)

F.1.3

Elderly (>=65 years)

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

Yes

F.3.3.6.1

Details of subjects incapable of giving consent

Parent(s) or legal guardian(s) of pediatric subjects must provide written informed consent.

Los padres o tutores legales de los sujetos pediátricos deben proporcionar un consentimiento informado por escrito.

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

F.4.2.2

In the whole clinical trial

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

Subject will return to previous standard of care treatment.

El sujeto volverá al tratamiento estándar de atención anterior.

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2021-08-13

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2021-08-06

P. End of Trial
P.	End of Trial Status	Ongoing

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials